Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537832 · ClinicalTrials.gov registry record
Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
A clinical trial, sponsored by Encoded Therapeutics.
- Terminated
- Registry status
- 58
- Enrollment target
NCT04537832: Clinical Trial study, sponsored by Encoded Therapeutics.
NCT04537832 is a clinical trial that was terminated before completion, run by Encoded Therapeutics. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04537832 was terminated before completion, sponsored by Encoded Therapeutics.
- TERMINATED
- Registry status
- 58 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.
Primary Outcome
Measured using monthly seizure frequency derived from seizure diaries.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2023-03-31 |
Why NCT04537832 stopped before completion
NCT04537832 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04537832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04537832 about?
NCT04537832 is a clinical study titled "Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies". This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.
What is the current status of trial NCT04537832?
This trial is currently terminated. The enrollment target is 58 participants. The study started on 2021-01-18. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT04537832?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04537832?
This trial is sponsored by Encoded Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI